The one OTC stock that needs to be on every investor’s radar right now is Regen BioPharma (OTCMKTS: RGBP). We alerted our subscribers last month that something big was brewing with RGBP stock when it signed a deal with Oncology Pharma (OTCMKTS: ONPH) to treat pancreatic and colon cancer and skyrocketed 957% in just two days.
We also alerted investors at how the company’s preferred shares also took off.
The key to trading OTC stocks is finding momentum BEFORE it happens and then be patient. Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.
We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.
Regen BioPharma is a biotech disruptor focused on immunology and immunotherapy. This innovative firm plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. The best part? The market seems to be starting to notice, judging by the returns it’s seen the last year.
As we said in the intro, when RGBP signed a deal with Oncology Pharma (OTCMKTS: ONPH) last month for the treatment of pancreatic and colon cancer, it popped 957% in just two days.
While the stock has pulled back somewhat since that announcement, we could be facing that same type of significant break-out potential. We will mention the catalysts, but needless to say, they look massive.
Based on these catalysts, the stock has had several one-day surges in May. For example, it surged by as much as 37% on May 7 and 35% on May 13.
Plus, with a low float of only about 568.2M shares, this is a stock that moves and moves explosively when its volume exceeds its average. On May 7, for example, the stock saw a volume of 445,397,849, while on May 13, it saw a volume of 175,221,093.
Source: Yahoo! Finance
This comes as the company is still riding high on a 16,000+% 52-week return and continues to make moves as a pharmaceutical disruptor.
What About RGBPP?
RGBPP is another way to play on RGBP’s upside potential. As we discussed in our previous RGBP report, RGBPP is RGBP’s preferred shares. The most significant difference between RGBP and RGBPP is the share structure.
Let’s take a deeper dive first and discuss the difference between preferred and common shares. Preferred shareholders do not have voting rights while common shareholders do. However, the caveat is preferred shareholders get the first claim on a company’s income and assets. In other words, they get first dibs on dividends and excess profits before common shareholders.
While RGBP closed May 13 up 6.54% compared to RGBPP, which closed up over 26.5%, returns over the long-term are not necessarily amplified for preferred shareholders. In fact, according to NTB Financial, “common stock has the potential to return higher yields over time through capital growth.” Take this 1-year chart comparing RGBP vs. RGBPP, for instance.
Source: Yahoo! Finance
Despite the potential for higher long-term appreciation, common shareholders also may incur more risks. For instance, if the company goes belly up, it’s the preferred shareholders who get paid before common shareholders. So if you’re on the more risk-off end, you get a similar type of upside without as many risks as a preferred shareholder.
What Are The Stock’s Earth-Shaking Catalysts?
According to this May 7, 2021 report, “the Regen stock has climbed by 37%,” “seems to be in the middle of another upward move,” and “might be back in focus among many investors.”
Furthermore, on May 13, 2021, Regen Biopharma signed a consulting agreement with Biotech Research Group and skyrocketed 27% on the news. Biotech Research Group is regarded as an FDA Specialist and Global Regulatory and Scientific Expert.
Biotech Research Group plans to help Regen Biopharma reinstate the inactive IND (investigational new drug) applications currently lying with the U.S FDA. The signing of the agreement marks the first step for Regen Biopharma towards reactivating those applications.
This could very well be a similar type of catalyst to the deal with Oncology Pharma.
BioTech Research Group
Biotech Research Group (BRG) is a scientific research organization reinvented. Of course, not all scientific research organizations are equal. However, Biotech Research Group separates itself from the pack with experts who work diligently to meet its clients’ needs worldwide.
This is a company led by high-quality doctors, researchers, toxicologists, epidemiologists, pathologists, and public health professionals in over 60 countries. BRG understands the importance of having its clients’ questions addressed and collaborating on their time.
Biotech Research Group understands the complexity of biologics development and the differences between pharmaceutical and medical device development. Its Biologics Consulting Group has the experience that expands beyond FDA Title 21 CFR Parts 1271 & 1272, product development, current good tissue practices, and quality compliance.
Biotech Research Group also has expertise with a wide range of medical devices across all classes. Thus, it has all the ingredients in place to potentially expedite the FDA 510k regulatory process.
The company’s pharmaceutical consulting group also has experts in ANDA Consultants, NDA Consultants, and IND Consultants to provide the best support for its clients and over 50 years of combined experience building strong relationships with FDA agents.
But beyond these operations from BRG that help RGBP skyrocket, Biotech Research Group has a diverse group of QA Consultants assisting clients in developing quality assurance programs from scratch. It also boasts specialty pharmaceutical consulting services and resources, and scientific and regulatory legal support and research, as well as expert testimony.
More On How Huge The Oncology Pharma Deal Is
While the BRG deal is yet another catalyst that may send the RGBPP stock to the moon, let’s revisit last month’s Oncology Pharma deal in case you need a refresher.
Last month, Regen BioPharma announced two deals with Oncology Pharma. One is between Oncology and Regen for treating pancreatic cancer. The other is between Regen’s wholly-owned subsidiary KCL Therapeutics, Inc, and Oncology to treat colon cancer.
Part of the deal included a nonrefundable fee of $55,000 paid to Regen no later than April 20, 2021- which obviously has passed. The deal also states that Oncology will:
(a) pay to Regen royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(b) pay to Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment
In the second deal, Oncology Pharma paid KCL Therapeutics a fee of 50,000 common shares (by April 20, 2021), along with:
(a) paying to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(b) paying to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment
As of mid-April, those 50,000 shares of Oncology Pharma were worth about $1,700,000.
More to Come
On top of the deals with Oncology Pharma and Biotech Research Group, Regen BioPharma is sitting on a very valuable patent portfolio. So it was just a matter of time before they started monetizing it. Just doing a Google patent search yields 23 results.
These deals further validate the premise that while the company was quiet over the last two years, Regen has been hard at work behind the scenes and the stock price year-to-date shows.
Expect more groundbreaking announcements shortly and for the stock price to perform accordingly and explosively.
Updating Its Filings
OTC stocks that have the STOP sign due to not filing financials can see explosive breakouts as they update. As we revealed last month, Regen BioPharma filed an 8-K that they intend to complete their financials. Once the company files for 2019 and 2020, the STOP sign will be removed. This will allow more brokers to list RGBP and RGBPP for their customers to trade.
Once this happens, watch out for the retail buzz. It could very well become the next darling of the Reddit WallStreetBets crowd.
Once RGBP stock clears a nickel, it’s blue skies ahead to a dime, followed by a quarter and dollar (s).
Numerous catalysts are coming up to make all this happen.
- Consulting agreement with Biotech Research Group.
- Deal with Oncology Pharma.
- Updated Its Filings.
- A valuable patent portfolio that the company only now is starting to monetize.
All we can say is that RGBP stock is one of the best bets for investors on the OTC Markets. But the best part? You can use either common shares or preferred shares to get exposure, no matter what type of investor you are.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.